Tag: Oncolytic immunotherapy
Vaxiion begins VAX014 phase 1 trial in non-muscle invasive bladder cancer
Vaxiion Therapeutics, a clinical stage biotech company based in California, has initiated a phase 1 clinical trial of its recombinant bacterial minicell-based oncolytic immunotherapy VAX014 ... Read More
Phase 3 trial of Pexa-Vec for advanced liver cancer initiated in China
South Korean biotech company SillaJen and Hong Kong-based Lee's Pharmaceutical have enrolled the first patient in China for a phase 3 trial called PHOCUS which ... Read More